Display search results for ** instead (9 products)
03 Mar 2017  |  North America
Digitalization Spending to Grow Rapidly to $82.01 Billion in 2020
Research Scope In 2015, automotive industry investments in key focus areas were about $19.57 billion. Growing digitalization and advancements in technology will increase the investments to $82.01 billion by 2020. The rapid pace of digitalization is transforming the component hardware-driven automotive sector to a software and solutions-focused ind...
20 Oct 2017  |  North America
Gain a Competitive Advantage Using Insights
This in-depth study of 1,934 IT decision makers was designed to measure the current use and future decision making behavior toward information technology (IT) around the globe and across verticals. More than half of the respondents were C-Level executives. IT solutions covered include Enterprise Mobility Management, eCommerce/mCommerce, Unified Com...
25 Oct 2017  |  North America
By 2025, Data Monetisation is Expected to Unravel ~$33 Billion in Opportunity for OEMs, with the Potential to Monetise $100 per Car Across 140 Unique Use Cases
This study analyses the strategies, growth analysis, competitive landscape, business models, and future focus areas of OEMs, data aggregators, usage-based insurance (UBI) companies, and tier 1 suppliers. OEMs, tier 1s, insurance companies, and data aggregators must focus on data services around smart mobility, connected cars, and autonomous vehicle...
24 Aug 2016  |  North America
A Deep Dive into Twelve Prominent Solutions
Not all customers, locations or users will move to cloud communications services. There are valid reasons to deploy UC solution on the customer premises. This Buyers' Guide overviews capabilities available with the flagship SMB platforms offered by North America's leading UC platform vendors. Details include: development direction, scale, performan...
04 Jul 2016  |  North America
The Next Generation of Cancer Therapies
Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibi...
USD 6,000.00 save 25 %
24 May 2017  |  North America
Over 10 Companies Poised to Launch Flying Cars by 2022, with OEMs and Other Major Industry Participants Set to Join them with Prototypes in the Following 5 Years
This study provides a comprehensive insight into the flying cars landscape. It discusses the evolution of flying cars and the need for them today, as well as mega trends favoring them. The technological challenges and supporting technologies to overcome them are included, and the various types of flying cars and profiles of key participants are pro...
USD 5,625.00 save 25 %
16 Aug 2016  |  North America
Emerging Business Models Drive Transformation
The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to c...
USD 5,250.00 save 25 %
03 May 2016  |  North America
Massive Gains for Vendors Who Can Win the Race to Identify Key Elements of Successful Cyber Defense Platforms
In 2015, network access control (NAC) proved to be among the most successful cyber defense platforms as NAC vendors experienced 30% YoY growth in revenues for appliances and related services. Frost & Sullivan anticipates continuing demand for NAC through 2020. NAC is a technology that can be used to provide immediate mitigation from cyber threats b...
USD 4,875.00 save 25 %
11 Nov 2016  |  North America
High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs
The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...
USD 4,500.00 save 25 %